English
|
中文
HOME
NEWS
EVENTS
Conference
Exhibition
Laws & Regulations
About Us
CAIVD & PCEM
CAIVD
PCEM
VIEW
About VIEW
Editorial Board
Contact
Search
News
Home
>
News
Autobio: Revenue of 1.678 billion yuan in the first half of 2021
2021-08-31
On August 17th, Autobio released a semi-annual performance report stating that the operating income was 1.678 billion yuan, an increase of 39.13% year-on-year; the net profit attributable to shareholders of listed companies was 413 million yuan, an increase of 50.63% year-on-year.
Jury Awards ArcherDx, MGH $4.7M in Qiagen Patent Infringement Lawsuit
2021-08-31
A federal jury on Friday ruled that Qiagen willfully infringed two patents owned by ArcherDx (now part of Invitae) and Massachusetts General Hospital and ruled that Qiagen must pay royalties and lost profits totaling about $4.7 million.
LumiraDx Scales Back on its SPAC
2021-08-30
LumiraDx reduced the terms of the valuation for its SPAC merger from $5 billion to$3 billion citing a decline in COVID-19 testing
Mount Sinai, Empire City Laboratories SARS-CoV-2 Tests Get FDA Emergency Use Authorizations
2021-08-30
The US Food and Drug Administration this week granted separate Emergency Use Authorizations for PCR-based SARS-CoV-2 tests developed by Mount Sinai Hospital and Empire City Laboratories.
Three Cases of Strategic Collaborations in August
2021-08-27
Genetron Health collaborates with Yikon Genomics, expanding S5 Platform's reach to reproductive health field; AmoyDx collaborates with Amgen to develop companion diagnostics for Japan market; AcornDx collaborates with BGI to develop accurate diagnosis on urinary system tumors
FDA Clears Thermo Fisher Scientific Oncomine Assay as CDx for Bile Duct Cancer Drug
2021-08-27
Thermo Fisher Scientific said on Wednesday that the US Food and Drug Administration has granted pre-market approval to the company's Oncomine Dx Target Test as a companion diagnostic to identify patients with isocitrate dehydrogenase-1 (IDH1) mutated cholangiocarcinoma (CCA) who may be candidates for treatment with ivosidenib (Servier Pharmaceuticals' Tibsovo).
MDxHealth H1 2021 Revenues Up 9 Percent As Testing Volumes Rebound
2021-08-27
MDxHealth reported Thursday after the close of the Belgian stock exchange that its revenues for the first half of 2021 increased 9 percent year over year.
Mindray reports first-half 2021 results, total sales reached CNY 12.778 billion
2021-08-26
August 25, Mindray (300760.SZ) announced financial results for the first half ended June 30, 2021. The first-half sales of CNY 12.778 billion increased 20.96% year-on-year. The net earnings attributable to common stockholders was CNY 4.344 billion, increasing 25.79% than the one in the last year.
AccessDx Acquires 2bPrecise From Allscripts
2021-08-26
AccessDx Holdings said Wednesday that it has acquired 2bPrecise, a service and technology provider that integrates genetic and genomic test results into electronic health records, from EHR giant Allscripts Healthcare Solutions for an undisclosed amount.
FDA Approves BD High-Throughput Cor System, HPV Screening Assay
2021-08-26
Becton Dickinson announced Wednesday that it has received US Food and Drug Administration approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of human papillomavirus.
Fosun Diagnostics Acquired 58.67% Equity of Suzhou Abcarta
2021-08-25
On August 20, Fosun Diagnostics, a holding subsidiary of Fosun Pharma, signed the investment agreement with Suzhou Abcarta. After the completion of the transaction, Fosun Diagnostics will hold about 58.67% equity of Suzhou Abcarta.
Genetron Health Posts 38 Percent Revenue Increase in Q2
2021-08-25
Genetron Health on Tuesday reported a 38 percent year-over-year increase in its second quarter revenues amid strong growth in sales from its LDT and IVD segments.
Cerba Research, ACT Genomics to Open Joint Lab Facility in Taiwan
2021-08-25
Cerba Research and ACT Genomics said on Tuesday that they have formed a joint venture to provide clinical trial services to clients throughout Asia Pacific through a new laboratory facility in Taiwan.
Joinstar SARS-CoV-2 Neutralizing Antibody Rapid Test (Fluorescence Dry Quantitative Immunoassay) was officially sold in foreign markets
2021-08-24
Recently, SARS-CoV-2 Neutralizing Antibody Rapid Test (Fluorescence Dry Quantitative Immunoassay) developed by Joinstar Biomedical Technology Co., Ltd. and Nanshan Pharmaceutical Research Institute of Guangdong province was officially sold to overseas markets.
Tellgen Corporation Q2 Revenue: Year-over-Year Increase in Net Profit of Nearly 10 Times
2021-08-24
On August 21, TELLGEN posted a 157.93% year-over-year increase on continued demand for its tumor and autoimmunity test.
Total:
3024
Pages:
202
First
Prev
1
..
135
136
137
138
139
140
141
..
202
Next
End